论文部分内容阅读
根据免疫组织化学检查,人卵巢癌相关抗原CA_(125)存在于上皮性卵巢肿瘤的腺腔上皮细胞膜上。临床上,以卵巢非粘液性单纯性原发癌患者血清中出现率高且浓度亦高,并与治疗效果密切相关,为卵巢癌血清标志被重视。作者术前测定良性子宫肿瘤患者血清的 CA_(125)水平,对鉴别有困难的子宫平滑肌瘤和子宫肌腺病进行鉴别,获得有意义的结果。研究对象及方法:64例正常者均系无症状并经妇科检查及超声检查排除子宫、卵巢肿瘤和妊娠的21～91岁妇女,19例良性子宫肿瘤均为术后摘除子宫病理检查确诊者,其中子宫平滑肌瘤11例、子宫肌腺病7例、两病同存者1例,各在术前、后取血清,置-20℃保存。用 CA_(125)RIA 箱(CENTOCOR,Inc,Ma-
According to immunohistochemical examination, human ovarian cancer associated antigen CA 125 (125) is present in the epithelial cell membrane of epithelial ovarian tumors. Clinically, patients with ovarian non-mucinous simple primary cancers have a high rate of occurrence in the serum and a high concentration, and are closely related to the efficacy of treatment. It is important for ovarian cancer serum markers. The authors determined the level of serum CA 125 in patients with benign uterine tumor before surgery, and identified the difficult to differentiate uterine leiomyoma and adenomyosis, and obtained meaningful results. Subjects and methods: All the 64 normal subjects were asymptomatic women who were 21 to 91 years old who were excluded by gynaecological examination and ultrasound examination to exclude uterus, ovarian tumor and pregnancy. 19 cases of benign uterine tumors were confirmed by postoperative uterine pathological examination. Among them, 11 cases of leiomyoma of the uterus, 7 cases of adenomyosis, and 1 case of both diseases coexisted. Serum was taken before and after each operation and stored at -20°C. With CA_(125) RIA box (CENTOCOR, Inc, Ma-